Impax Loses Bid For Generic Version Of Rilutek

Law360, New York (September 1, 2004, 12:00 AM EDT) -- Impax Laboratories Inc.'s proposed generic version of Rilutek infringes on Aventis SA's patent for the brand version of the drug, a U.S. federal court has ruled.

In its decision, Judge Joseph J. Farnan Jr. of the U.S. District Court for the District of Delaware ruled that Aventis Pharmaceutical's patent 5,527,814 related to the use of Rilutek is valid, enforceable and infringed by IMPAX's proposed generic product.

Impax had received approval from the Food and Drug Administration for its version of the drug, Riluzole 50mg, in January...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.